Pharmaceutical Executive
London, UK-Changes to the law on human embryo research could herald a new era for UK biotech research. The government feared its proposals to allow the cloning of embryos as sources for stem cells for research would be thrown out by the House of Lords-where a powerful body of opinion holds that they represent a slippery slope toward reproductive cloning-but the proposals passed by a surprisingly large majority.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Artificial Intelligence Makes Possible a Multiomic Approach in Oncology Drug Discovery
January 7th 2025While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure prediction, and drug optimization.